<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03413410</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-16-12344</org_study_id>
    <nct_id>NCT03413410</nct_id>
  </id_info>
  <brief_title>A Multi-Center Study on the Metoprolol Optimal Dosing Pathway of Metoprolol Application in Chinese Patients With Acute Coronary Syndrome</brief_title>
  <official_title>A Multi-Center Study on the Metoprolol Optimal Dosing Pathway of Metoprolol Application in Chinese Patients With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yun Dai Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to test the feasibility and tolerability of the metoprolol optimal dosing&#xD;
      pathway by observing the percentage of patients achieving target dose followed the pathway on&#xD;
      ACS patients during hospitalization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute coronary syndrome(ACS) is one of the main manifestations of cardiovascular disease and&#xD;
      one of the main causes for hospitalization in adults.&#xD;
&#xD;
      Previous studies showed that β-receptor blockers can reduce ACS patients' cardiovascular risk&#xD;
      in both acute phase and secondary prevention. We summarized the metoprolol optimal dosing&#xD;
      pathway based on Chinese and foreign guidelines as well as Chinese clinical practice.&#xD;
&#xD;
      Primary endpoint is the percentage of patients achieving target dose at time of discharge.&#xD;
&#xD;
      Secondary endpoints are the mean HR &amp; BP at discharge and during the follow up period of the&#xD;
      Patients who have achieved target dose at discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients achieving target dose</measure>
    <time_frame>1 month</time_frame>
    <description>The percentage of patients achieving target dose of 95mg/d at the time of discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean heart rate</measure>
    <time_frame>1 month</time_frame>
    <description>The mean HR after achieving target dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean blood pressure</measure>
    <time_frame>1 month</time_frame>
    <description>The mean BP after achieving target dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of patients who experienced bradycardia with symptoms</measure>
    <time_frame>1 month</time_frame>
    <description>The percentage of patients who experienced bradycardia with symptoms during hospitalization and for 1 month after discharge, respectively</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>ACS - Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Metoprolol interventional group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a multi-center, prospective, open label, single-arm interventional study.&#xD;
Patients hospitalized for ACS, fulfilling all of the inclusion criteria and none of the exclusion criteria can be enrolled in this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Patients with acute coronary syndrome take metoprolol during hospital and after discharge in the optimal dosing pathway.</description>
    <arm_group_label>Metoprolol interventional group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or above;&#xD;
&#xD;
          -  Hospitalized due to acute coronary syndrome;&#xD;
&#xD;
          -  Able and willing to provide written informed consent and to comply with the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac shock;&#xD;
&#xD;
          -  Unstable heart failure;&#xD;
&#xD;
          -  Beta-agonist therapy on a continuous or intermittent basis;&#xD;
&#xD;
          -  Hypotension (BP&lt;90/60 mmHg) or bradycardia (HR&lt;50 bpm) with symptoms;&#xD;
&#xD;
          -  Sick sinus syndrome;&#xD;
&#xD;
          -  Ⅱ~Ⅲ atrioventricular block;&#xD;
&#xD;
          -  Killip &gt;Ⅱ;&#xD;
&#xD;
          -  Suspected acute myocardial infarction with heart rate&lt;45 beats/min, P- R interval&gt;0.24&#xD;
             sec or systolic blood pressure &lt;100 mmHg;&#xD;
&#xD;
          -  Existing contraindication for metoprolol or allergic to metoprolol or any excipients;&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product during the&#xD;
             last 3 months;&#xD;
&#xD;
          -  Previous enrolment in the present study;&#xD;
&#xD;
          -  Subjects the investigator thinks not suitable for this study. E.g. cancer etc.;&#xD;
&#xD;
          -  Inability to sign the informed consent form;&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yundai Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The General Hospital of PLA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dandan Li, MD</last_name>
    <phone>+8613810545564</phone>
    <email>ldd301heart@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The General Hospital of PLA</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dandan Li, MD</last_name>
      <phone>+8613810545564</phone>
      <email>ldd301heart@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>July 18, 2019</last_update_submitted>
  <last_update_submitted_qc>July 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Yun Dai Chen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

